期刊文献+

毛壳素显著抑制柯萨奇病毒B3的体外复制

Chaetocin significantly inhibits coxsackievirus B3 replication in vitro
下载PDF
导出
摘要 柯萨奇病毒B3(CVB3)是一种常见的人类病原体,与多种疾病有关。本研究旨在探讨球毛壳菌代谢产物毛壳素对CVB3在体外培养细胞系中复制的影响。结果显示,毛壳素显著抑制CVB3在体外培养细胞系中的复制。250nmol/L毛壳素可使CVB3感染的HeLa细胞相对存活率从未加毛壳素时的(21.9±1.8)%提高至(70.1±4.3)%。同时,毛壳素处理的HeLa细胞中病毒产量仅为对照组的(5.3±0.8)%,而病毒RNA水平也仅为对照组的(13.0±8.3)%。毛壳素也可使CVB3感染的Vero细胞相对存活率从(64.6±1.7)%提高至(87.2±4.8)%。毛壳素的这种抑制作用可被抗氧化剂N-乙酰半胱氨酸部分抑制。研究毛壳素抑制病毒复制的具体作用机制将有助于新型抗病毒药物的研制。 .Coxsackievirus B3 (CV133) is a common human pathogen associated with many diseases. The present paper aimed to investigate the inhibitory effect of chaetocin, a metabolite isolated from Chaetomium, on CVB3 replication in vitro. Treatment of CVB3-infected HeLa cells with 250 nmol/L chaetocin increased the relative cell viability from 21.9% to 70.1%, while the production of progeny virus in chaetocin-treated ceils was only 5.3% of that in untreated cells. The viral RNA level in chaetocin-treated cells was also reduced to about 13.0% of the control. Chaetocin treatment also increased the relative cell viability of CV133-infected Vero cells from 64.6% to 87.2%. This inhibitory effect of chaetocin was partially attenuated by the antioxidant agent N-acetyl cysteine. Further analysis of the mechanism may help the development of antiviral drug against CVB3 and other enteroviruses.
出处 《微生物与感染》 2013年第3期138-143,共6页 Journal of Microbes and Infections
基金 国家自然科学基金(30900561)
关键词 柯萨奇病毒B3 毛壳素 抗病毒药物 Coxsackievirus B3 Chaetocin Antiviral
  • 相关文献

参考文献24

  • 1Udagawa S, Muroi T, Kurata H, Sekita S, Yoshihira K, Natori S, Umeda M. The production of chaetoglobosins, sterigmatocystin, O-methylsterigmatocystin, and chaetocin by Chaetomium spp. and related fungi [J ]. Can J Microbiol, 1979, 25(2) :170-177.
  • 2Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 [J]. Nat Chem Biol, 2005, 1(3) : 143-145.
  • 3Iwasa E, Hamashima Y, Fujishiro S, Higuchi E, Ito A, Yoshida M, Sodeoka M. Total synthesis of ( + )-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity [J]. J Am Chem Soc, 2010, 132 (12): 4078-4079.
  • 4Illner D, Zinner R, Handtke V, Rouquette J, Strickfaden H, Lanctot C, Conrad M, Seller A, Imhof A, Cremer T, Cremer M. Remodeling of nuclear architecture by the thiodioxoxpiperazine metabolite chaetocin [J]. Exp Cell Res, 2010, 316(10) : 1662-1680.
  • 5Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, Vey N, Altucci L, Collette Y. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 [J]. Leukemia, 2012, 26(4):662-674.
  • 6Lee YM, Lim JH, Yoon H, Chun YS, Park JW. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1a pre-mRNA in mice and in vitro [J]. Hepatology, 2011, 53(1) :171-180.
  • 7Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress [J]. Blood, 2007, 109(6):2579-2588.
  • 8Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response[J]. FEBS Lett, 2011, 585(22) : 3549-3554.
  • 9Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC. The antieancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase [J].Antioxid Redox Signal, 2009, 11(5): 1097-1106.
  • 10Rose NR. Myocarditis: infection versus autoimmunity [J].J Clin Immunol, 2009, 29(6) : 730-737.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部